GSK plc (GSK) Form 6-K — Sep 15, 2026
GSK plc announced it has agreed to acquire a potential best-in-class trispecific T cell-engager (TCE) for multiple myeloma from privately held Chimageen Biosciences, with the agreement carrying a total potential value of up to $750 million via an upfront fee plus success-based milestone payments. The asset is designed to bind T cells while targeting two validated tumour-associated antigens, aiming for deeper, more durable responses and better tolerability than current TCEs, with Phase I entry expected in 2027.
Key figures
- Deal Value Usd
- up to $750 million
- Upfront Fee
- not disclosed (upfront plus success-based development and commercial milestones)
- Phase1 Entry Year
- 2027
- Us Tce Market2032
- expected to exceed $10 billion
- Total Potential Value
- up to $750 million
- Annual Global Multiple Myeloma Cases
- ~180,000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.